Nephros

Nephros Days Payable Outstanding

The Days Payable Outstanding (DPO) of Nephros (NEPH) as of Nov 1, 2026 is 45.67. In the previous year, Days Payable Outstanding (DPO) was 43.55 — a change of 4.87% (higher).

Days Payable Outstanding

45.67

YoY

4.87%

Last updated:

Days Payable Outstanding (DPO) of Nephros is 2025 45.67 . Days Payable Outstanding (DPO) of Nephros was 2024 43.55 . It decreases by 4.87% higher compared to the previous year.

The Nephros Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
122.84 USD
Jan 1, 2019
82.36 USD
Jan 1, 2020
42.32 USD
Jan 1, 2021
106.22 USD
Jan 1, 2022
51.51 USD
Jan 1, 2023
54.63 USD
Jan 1, 2024
43.55 USD
Jan 1, 2025
45.67 USD
The Nephros Days Payable Outstanding history
YEARDays Payable OutstandingYoY
45.67+4.87%
43.55-20.27%
54.63+6.06%
51.51-51.51%
106.22+150.97%
42.32-48.61%
82.36-32.95%
122.84-41.45%
209.81+0.81%
208.11-22.69%
269.21-70.59%
915.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nephros Stock analysis

What does Nephros do? Nephros, Inc. generates revenue through its Water Filtration and Renal Products segments. The Water Filtration segment sells high-performance water purification filters for hospitals, healthcare facilities, dialysis centers, commercial facilities, military, and outdoor recreation markets. The Renal Products segment offers a second-generation hemodiafiltration system for end-stage renal disease patients. Products include ultrafiltration systems used in medical and commercial applications, with subsidiaries Biocon 1, LLC, Aether Water Systems, LLC, and Specialty Renal Products, Inc. supporting sales and development. The company's water filtration products are sold to hospitals, dialysis centers, and commercial facilities, while the hemodiafiltration system targets healthcare providers treating ESRD patients. Subsidiaries handle specialized development and distribution, ensuring market coverage across medical and commercial sectors. Revenue streams are derived from both segments, with products serving healthcare infrastructure and renal treatment needs. Nephros, Inc. focuses on medical device solutions for renal disease and water purification, leveraging its subsidiaries to expand market reach. The Water Filtration segment serves healthcare and commercial clients, while the Renal Products segment addresses ESRD treatment through advanced hemodiafiltration technology, creating a diversified revenue model. Nephros is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nephros stock

Days Payable Outstanding (DPO) of Nephros is 45.67 in 2025.

Days Payable Outstanding (DPO) of Nephros changed from 43.55 to 45.67, representing a 4.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Nephros since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Nephros with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Nephros

All Key Metrics — Nephros